US › Healthcare

Sangamo Therapeutics Inc (SGMO)

US · Healthcare · Biotechnology

$0.070.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.4M
Revenue YoY
-77.6%
Net profit
$-31.0M
Profit YoY
-1.3%
EPS
$-0.08
EPS estimate
$0.04
Net margin
-2,149.4%

EPS came in at -0.08 against a street estimate of 0.04 — a miss of 300.0%.

Key statistics

Market cap
$30.7M
Forward P/E
0.4
P/B
18.13
Book value
$-0.05
EPS (TTM)
$-0.38
52-week high
$0.77
52-week low
$0.06
50-day MA
$0.15
200-day MA
$0.37
Beta
1.29

Analyst view

Analysts rate Sangamo Therapeutics Inc a buy (5 buy, 2 hold, 0 sell out of 7) with an average price target of $1.50.

Shareholding

Insiders
1.76%
Institutions
25.84%

Largest institutional holders

FundStake
Armistice Capital, LLC9.75%
Vanguard Capital Management, LLC3.07%
Vanguard Group Inc2.90%
Two Sigma Investments LLC1.51%
Balyasny Asset Management LLC1.28%
Geode Capital Management, LLC1.10%
BlackRock Inc1.10%
Two Sigma Advisers, LLC1.05%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sangamo Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.